# Olorunseun O. Ogunwobi, MD, PhD, MS-CTS

Full Professor
Department of Biological Sciences, Hunter College of The City University of New York

Founding Director
Hunter College Center for Cancer Health Disparities Research (CCHDR)

Adjunct Faculty
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medicine

Belfer Research Building
413 E 69th Street, Room 426
New York, NY 10021
ogunwobi@genectr.hunter.cuny.edu
Tel: 212-896-0447 (office); 352-792-5979 (cell)
Fax: 212-772-5227
Websites: http://Ogunwobi.bioweb.hunter.cuny.edu
http://www.speechregionalpartnership.org/
http://cchdr.org/
https://www.gc.cuny.edu/people/olorunseun-ogunwobi

## Education

**PhD** Cell and Molecular Medicine, School of Medicine, University of East Anglia, Norwich, United Kingdom. 2007
*Dissertation: Etiological factors and drug targets in colonic and esophageal adenocarcinoma*
(Advisor: Ian Beales, MD, FRCP)

**MS-CTS** Clinical and Translational Science, Clinical and Translational Science Institute, University of Florida, Gainesville, Florida. 2013
*Thesis: miR-198 in pancreatic cancer progression and management*
(Advisors: Chen Liu, MD, PhD and Thomas George Jr, MD, FACP)

**MSc** Biomedical Science, School of Biological Sciences, University of Hull, Hull, United Kingdom. 2004
*Thesis: A study of the potential of matrix assisted laser desorption/ionization time-of-flight mass spectrometry as a technique for clinical bacterial identification*
(Advisor: Tim Paget, PhD)

**MBBS** Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria. 2000

## Professional Employment

**Full Professor (tenured)** 2022 - 2023
Department of Biological Sciences
Hunter College of The City University of New York, New York.

**Co-Founder** 2022 - present
UTR Therapeutics Inc

**Associate Professor (tenured)** 2020 – 2022
Department of Biological Sciences
Hunter College of The City University of New York, New York.

**Founding Director** 2018 - present
Hunter College Center for Cancer Health Disparities Research
Hunter College of The City University of New York, New York.

**Co-Founder** 2017 - present
NucleoBio Inc

**Adjunct Faculty** 2015 - present
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medicine
Cornell University, New York.

**Faculty** 2014 - present
PhD program in Molecular, Cellular, and Developmental Biology
PhD program in Biochemistry
The Graduate Center
City University of New York

**Associate Professor (tenure-track)** 2014 – 2020
Department of Biological Sciences
Hunter College of The City University of New York, New York.

**Post-Doctoral Fellow in Cancer Biology** 2009 – 2013
Department of Pathology, Immunology and Laboratory Medicine
University of Florida, Gainesville, Florida.

**Post-Doctoral Research Scientist**, Department of Pathology 2008 - 2009
School of Medicine, Virginia Commonwealth University, Richmond, VA.

**Post-Doctoral Research Associate**, School of Medicine, 2007 – 2008
University of East Anglia, Norwich, United Kingdom.

**Tutor**, Medical Degree Program, School of Medicine, 2005 - 2008
University of East Anglia, Norwich, United Kingdom.

**Research Associate**, School of Medicine, University of East Anglia 2004 - 2005
Norwich, United Kingdom.

**Medical Officer**, Ipaja Primary Health Care Center, Ipaja 2001 - 2002
Lagos State, Nigeria.

**House Physician**, University College Hospital, Ibadan 2000 - 2001
Nigeria.

## Career and Research Interests

1. Laboratory research: The goal of my laboratory is to elucidate the molecular mechanisms of progression of solid organ cancers with known disparities in incidence, prevalence, or outcomes. Ongoing studies include examination of the role and molecular mechanisms of circulating tumor cells, oxytocin and the oxytocin receptor, and non-coding RNAs derived from the Plasmacytoma Variant Translocation 1 (PVT1) gene locus. A new area of interest in my laboratory is epitranscriptomics, and utilization of 3'UTR engineering to target oncogenic transcripts.

2. Research education: Through funding from the National Cancer Institute and other agencies, I am committed to developing a cancer research education program through which mentorship is provided to underrepresented minority trainees in collaborative and multidisciplinary translational cancer research. In this regard, I serve as the Research Education Core Leader for the Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) funded by National Cancer Institute grant numbers U54 CA221704 and U54 CA221705.

3. Leadership in cancer health disparities research: As founding director of the Hunter College Center for Cancer Health Disparities Research (CCHDR), I lead a team of researchers and staff involved in translational laboratory research, community-based research, and in administering the multiple cores of major National Cancer Institute – funded U54 center grants (U54 CA221704 and U54 CA221705). Also, I participate on NIH review panels to review cancer health disparities research grant proposals. In addition, I have forged strong collaborations with multiple community-based organizations in New York City (e.g Arthur Ashe Institute for Urban Health, and Coalition against Hepatitis in People of African Origin (CHIPO) – New York City, African Services Committee), Columbus Public Health, and with the New York City Department of Health and Mental Hygiene to address cancer health disparities.

## Grants/Funding (Total > $15.07 million)

Active

3U54CA221704-03S1

National Institutes of Health / National Cancer Institute
Project Period: 09/01/2020 - 08/31/2023
Ogunwobi O (Contact PI); Ma G (Multiple PI)
Title: TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership
Role: Contact Principal Investigator
Total amount: $386,988

U54 CA221704
NATIONAL INSTITUTES OF HEALTH/NATIONAL CANCER INSTITUTE
Project Period: 09/01/2018 - 08/31/2023
OGUNWOBI, OLORUNSEUN (Contact Principal Investigator)
Multiple Principal Investigators: MA, GRACE; ERBLICH, JOEL; ISSA JEAN-PIERRE
*Title: TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership*
Roles: Contact Principal Investigator, Administrative Core Leader, and Research Education Core Leader
Total amount: $5,373,858

U54 CA221705
NATIONAL INSTITUTES OF HEALTH/NATIONAL CANCER INSTITUTE
Project Period: 09/01/2018 - 08/31/2023
MA, GRACE (Contact Principal Investigator)
Multiple Principal Investigators: OGUNWOBI, OLORUNSEUN; ERBLICH, JOEL; ISSA JEAN-PIERRE
*Title: TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership*
Roles: Multiple Principal Investigator
Total amount: $8,060,788

No number
Irving A. Hansen Memorial Foundation
Project Period: 08/01/2022 - 08/31/2023
Ogunwobi O (PI)
*Title: Dietary behavior and cancer in underserved minority populations in New York City*
Role: Principal Investigator
Total amount: $25,000

XSeed Award
Deerfield
Project Period: 04/01/2023 –
Awah, Chidiebere (PI)
*Title: Nanocage delivered engineered destabilized 3'UTR of c-MYC therapeutically degrades c-MYC-STAT5A/B-PDL-1 complex in metastatic triple-negative breast cancer and inhibited primary tumor and metastasis in vivo*
Role: Sub-award PI
Total amount: $250,000

No number

Black, Race and Ethnic Studies Initiative (BRESI)
Project Period: 09/01/2022 - 06/30/2023
Matsui H (PI); Ogunwobi O (Co-PI)
*Title: Impacting prostate cancer disparity in Black men using RNA nanotherapeutics*
Role: Co-Principal Investigator
Total amount: $10,000

1 R01 CA239603
NATIONAL INSTITUTES OF HEALTH/NATIONAL CANCER INSTITUTE
Project Period: 02/06/2020 - 01/31/2025
BARGONETTI, Jill (PI)
*Title: The Role of the Mutant p53- PARP-MCM Pathway in Triple Negative Breast Cancer*
Role: Co-Investigator
Total amount: $389,255 in Year 1; $368,017 in Year 2; $328,171 in Year 3

MetAvivor Advisors Award
MetAvivor
Bargonetti, Jill (PI)
Project Period: 01/01/2022 – 12/31/2023
*Title: Targeting Metastatic Breast Cancer Through the Mutant p53-PARP Axis*
Role: Collaborator
Total amount: $200,000

Award Number: 2050532
National Science Foundation
Project Period: 03/15/2021 - 02/29/2024
Oyekoya, Oyewole (PI)
*Title: Research Experience for Undergraduates in Immersive 3D Visualization*
Role: Research Mentor
Total amount: $404,964

1P50CA254897-01A1
NATIONAL INSTITUTES OF HEALTH/NATIONAL CANCER INSTITUTE
Project Period: 08/16/2021 - 06/30/2026
ISSA, Jean-Pierre (Contact PI); BAYLIN, Stephen B (MPI); JONES, Peter A (MPI)
*Title: Epigenetic Therapies - New Approaches*
Role: Internal Advisory Board Member
Total amount: $2,269,729

2845
CUNY Interdisciplinary Research Grant (IRG) Program
Project Period: 02/15/2021 - 08/31/2023
Ogunwobi, Olorunseun (Lead PI); Co-PIs (W. Qiu, M. Yeh, C. Pan)
*Title: Molecular epidemiology of PVT1 and disparities in susceptibility to COVID-19*
Role: Lead PI

Total amount: $40,000

64718-00 52
PSC-CUNY Research Award Program
Project Period: 07/01/2021 - 12/31/2022
Ogunwobi, Olorunseun
*Title: Tumor suppressive mechanisms of miR-1207-3p in metastatic castration-resistant prostate cancer*
Role: Principal Investigator
Total amount: $12,000

KL2TR002385
NIH/NCATS/CTSC
Project Period: 01/01/2023 - 01/01/2024
McClure, Timothy (PI)
*Title: Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)*
Role: Mentor
Total amount: In Kind Contribution

Pending

No number (already selected for funding; awaiting details)
National Pediatric Cancer Foundation
Project Period: To Be Determined
Weiser, Dan (Lead PI); Ogunwobi, Olorunseun (Co-PI); Awah, Chidiebere (Co-PI)
Title: Engineered destabilized AU rich elements of c-MYC 3'UTR as therapeutics for c-MYC driven pediatric cancers
Role: Co-PI
Total amount: $2.3 million

R01
NATIONAL INSTITUTES OF HEALTH
Project Period: 2023 - 2028
Xie, Lei (PI)
*Title: Systems pharmacology-oriented humanized phenotype screening for precision drug discovery*
Role: Co-Investigator

Completed

T32HL135465
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Project Period: 07/01/2017 – 06/30/2022

Angulo, Jesus (PI)
*Title: HUNTER-WEILL T32 TRANSDISCIPLINARY RESEARCH TRAINING*
Role: Mentor (Primary Advisor to Trisheena Harricharran who graduated with Master of Science from Weill Cornell Graduate School of Medical Sciences in 2019 and PhD from The City University of New York in 2020)

Pre-Pilot Award
Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH)
Project Period: 12/15/2021 – 12/14/2022
Priyanka Ghosh (Graduate student trainee)
Title: *Reciprocal Regulation of MiR-1207-3p by its Molecular Target FNDC1 in Prostate Cancer*
Role: Mentor
Total amount: $10,000

Pilot Award
Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH)
Project Period: 07/15/2020 – 12/14/2021
Michelle Naidoo (Pre-doctoral trainee)
Title: *MicroRNA-1205 Regulation of FRYL and AURKA in Cell Lineage Plasticity in Prostate Cancer*
Role: Mentor
Total amount: $12,825

Pilot Award
Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH)
Project Period: 07/15/2020 – 12/14/2021
Fayola Levine (Graduate student trainee)
Title: *PVT1 Exon 9 as a Regulator of Claudin Expression in Triple Negative Breast Cancer*
Role: Mentor
Total amount: $12,825

Pre-Pilot Award
Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH)
Project Period: 07/15/2020 – 12/14/2021
Cristina Zambrano (Research Associate)
Title: *Nutritional Mechanisms of Early Onset Colorectal Cancer in Hispanics*
Role: Mentor
Total amount: $8,000

Pre-Pilot Award
Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH)
Project Period: 07/15/2020 – 12/14/2021
Kamran Khan (Graduate student trainee)

Title: *Endostatin Regulation of MHC 1 as a Mechanism of Immune Evasion by Circulating Tumor Cells*
Role: Mentor
Total amount: $8,000

Pilot Award
Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH)
Project Period: 07/15/2019 – 02/28/2021
Gargi Pal (Post-doctoral trainee)
Title: *Viral Delivery of miR-207-3p as a Therapeutic Option for Aggressive Prostate Cancer in Black Males*
Role: Mentor
Total amount: $15,000

Pre-Pilot Award
Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH)
Project Period: 07/15/2019 – 02/28/2021
Michelle Naidoo (Pre-doctoral trainee)
Title: *MicroRNA-1205 as a Tumor Suppressor in Aggressive Prostate Cancer in Black Males*
Role: Mentor
Total amount: $10,000

Pre-Pilot Award
Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH)
Project Period: 07/15/2019 – 02/28/2021
Fayola Levine (Graduate student trainee)
Title: *PVT1 in Triple Negative Breast Cancer in Black Women*
Role: Mentor
Total amount: $10,000

Pre-Pilot Award
Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH)
Project Period: 07/15/2019 – 02/28/2021
Oluwatoyin Odumuwagun (Graduate student trainee)
Title: *Oxytocin as a Biopsychosocial Modulator in Hepatocellular Carcinoma*
Role: Mentor
Total amount: $5,000

PI, CUNY Interdisciplinary Research Grant 07/2017–06/2019
Research Foundation of The City University of New York
*Title: Diet and cancer in New York City minority populations*
Total amount: $40,000

PI, RCMI Translational Research Network (RTRN) Small Grants Award 07/2016-06/2018

NIH/NIMHD/RTRN
*Title: Non-coding RNA-based biomarker discovery for clinical applications in prostate cancer in males of African ancestry*
Total amount: $40,000

PI, Center for Translational and Basic Research (CTBR) Pilot Award 12/2016-06/2018
NIH/NIMHD/CTBR
*Title: Molecular mechanisms and clinical applications of miR-1207-3p in prostate cancer*
Total amount: $50,000

PI, Innovation Corps Teams Award (Award Number:1645443) 06/2016-01/2018
National Science Foundation
*Title: I-Corps: Commercialization of biomedical applications of innovative technologies created from PVT1 non-coding RNA research*
Total amount: $50,000

PI, Carnegie African Diaspora Fellowship Program (CADFP) Mini-Grant for Conference Participation 05/2018-07/2018
Institute of International Education/Carnegie Corporation of New York
*Title: Two novel synthetic analogs of miR-1207-3p, NB5 and NB1207, target AR-V7 and c-MYC and demonstrate in vivo therapeutic efficacy in metastatic castrate-resistant prostate cancer (mCRPC)*
Total amount: $2,000

PI, Professional Staff Congress-City University of New York (PSC-CUNY) Enhanced Award 07/2016-12/2017
PSC-CUNY
*Title: Novel synthetic biotinylated miR-1207-3p duplex for discovery and therapeutic applications in prostate cancer*
Total amount: $12,000

Co-PI, Innovation Seed Funding Award 01/2016-01/2017
New York State Prostate Cancer Fund
*Title: Novel approaches to targeting survival signals in prostate cancer*
Total amount: $75,000

PI, Weill Cornell Clinical and Translational Science Center (CTSC) Pilot Award 05/2015-05/2017
NIH/NCATS/CTSC
*Title: PVT1 exon 9 and aggressive prostate cancer in Black men*
Total amount: $89,768

PI, Community Planning Grant 2016
NIH/NCATS/CTSC
*Title: Community engagement for prostate cancer research*
Total amount: $5,000

Co-PI, Pilot Project Award, 2014-2016
NIH/NIMHD/CTBR
*Title: MDM2 Oncogenic Functions Promoting Metastasis and Circulating Tumor Cells*
Total amount: $138,828

PI, Innovation Seed Funding Award, 2014-2015
NIH/NIMHD/CTBR
*Title: PVT1 and racial disparity in aggressive prostate cancer*
Total amount: $20,000

PI, President's fund for faculty advancement 2015
Hunter College President's Office
*Title: PVT1 exon 9 in prostate cancer in Black men*
Total amount: $4,500

Mentor, RTRN Small Grants Program, 2014-2015
Research Centers in Minority Institutions Translational Research Network/NIMHD/NIH
*Title: Evaluation of Vernonia cinerea (Vc) in the Treatment of Cancer*
Mentee: Leng Chang, PhD
Total amount: $40,000

Mentor, New York City Louise Stokes Alliance 2014-2015
For Minority Participation in Science, Technology, Engineering and Mathematics
*Title: Regulation and Function of Micro RNA-1205 in Prostate Epithelial Cells*
Mentee: Victoria Durojaiye
Total amount: $8,000

PI, AACR-FNAB Fellows Grant, American Association for Cancer Research 2012-2014
*Title: Mechanisms of metastasis in pancreatic cancer*
Total amount: $35,000

NIH T32 Postdoctoral Fellowship, University of Florida 2010 - 2013
*Title: Role of epithelial-mesenchymal transition in liver cancer metastasis*
Total amount: ~$150,000

PI, Experimental Pathology Innovative Grant, University of Florida 2012 - 2013
*Title: Circulating tumor cell biology and mechanisms of therapeutic resistance in pancreatic adenocarcinoma*
Total amount: $5,000

PI, Experimental Pathology Innovative Grant, University of Florida 2011 - 2012
*Title: Mechanisms of metastasis in colon cancer*
Total amount: $5,000

Co-PI, Big C Cancer Research Grant, Norwich, United Kingdom 2006 - 2008

*Title: AMP-activated protein kinase in esophageal adenocarcinoma*
Total amount: ~£50,000

PI, Institute of Biomedical Science Research Grant 2004 - 2005
*Title: Leptin in esophageal adenocarcinoma*
Total amount: ~£5,000

Investigator, NNUH Bicentenary Trust Studentship 2003 - 2006
University of East Anglia, UK
*Title: Leptin in esophageal adenocarcinoma*

## Honors

Jefferson Science Fellow 2023 – 2024
United States Agency for International Development / National Academies of Sciences, Engineering, and Medicine

Long Service Award 2023
PLOS ONE Editorial Board

Presidential Award for Excellence in Scholarship or Creative Activity 2022
(One of only two winners in 2022)
Hunter College of The City University of New York
https://drive.google.com/file/d/1j3R7L0DQ1TDyzH_NdMWhM3eEj5B3zq7N/view?usp=sharing

Fellow of The New York Academy of Medicine 2021

Special recognition at City University of New York Innovation Scholarship & Celebration 2021 2021
https://twitter.com/ChancellorCUNY/status/1394469557834760194?s=20

Carnegie African Diaspora Fellow 2017
Carnegie Corporation of New York

Minority-Serving Institution Faculty Scholar Award 2014, 2015, 2016
American Association for Cancer Research.

Minority Scholar in Cancer Research Award, 2013, 2014
American Association for Cancer Research.

Scholar Abstract Award 2013
Translational Science 2013, April 17-19, 2013, Washington DC
Sponsored by the Association for Clinical and Translational Science (ACTS) and the American Federation for Medical Research (AFMR)

Advanced Postgraduate Program in Clinical Investigation Scholar, 2012
NIH/NCATS/Clinical and Translational Science Institute
University of Florida.

Minority Scholar in Cancer Research Award, 2012
American Association for Cancer Research.

Oral presentation prize, Surgery Research Day, 2007
Norfolk and Norwich University Hospital, Norwich, United Kingdom.

General Travel Grant, 2007
Biochemical Society, London, United Kingdom.

Young Researchers' Travel Grant, Tebu-Bio 2007

Travel Grant for the best papers by young authors 2006
United European Gastroenterology Week (UEGW), Berlin, Germany

Paper presented at the British Society of Gastroenterology 2006
annual meeting in Birmingham, UK was given special recognition
through a press release from the British Society of Gastroenterology.

Travel Grant for the best papers by young authors 2005
United European Gastroenterology Week (UEGW), Copenhagen, Denmark.

Oral presentation selected as one of the key papers for special coverage 2005
in the United European Gastroenterology Week 2005 Congress Newspaper.

Research accomplishments acknowledged on page 5, 2005
issue number 24 of The Pulse, a publication of the Norfolk and Norwich University Hospital NHS Trust.

Institute of Health, University of East Anglia, Scholarship Fund 2005

University of Hull International Student Scholarship 2002-2003

Shell Petroleum Development Corporation Scholarship 1993-2000

**Professional Service**

Reviewer, 2023 Interdisciplinary Research Grant program 2023
The City University of New York

Committee Member, Black, Race and Ethnic Studies Initiative 2022-present
The City University of New York

Ad hoc Member, NCI RFA-CA-21-063 “A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials” (CUSP2CT) (U01) 2022
Center for Scientific Review, National Institutes of Health

Member, Executive Steering Committee 2022
Hunter College Multi-year Strategic Planning Effort

Ad hoc Reviewer, Prostate Cancer Research 2022-present
London, England

Ad hoc Reviewer, Worldwide Cancer Research 2022-present
Edinburgh, Scotland

Ad hoc Reviewer, Health & Social Care Research & Development 2021-present
Public Health Agency, Belfast, Northern Ireland

Co-Chair, Coalition against Hepatitis in People of African Origin (CHIPO) 2021-present
New York City

Scientist Reviewer 2021-present
Prostate Cancer Research Program (PCRP)
Congressionally Directed Medical Research Programs (CDMRP)

Co-Chair, Hunter College Committee on Strategic Planning for Research 2021-2022

Nominations Committee Member 2021-present
Molecular, Cellular, and Developmental Biology PhD Program
The Graduate Center, City University of New York

Program Committee Member 2021
14th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

Scientific Review Committee Member 2021
14th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

PhD Thesis External Examiner 2021
The University of Queensland, Brisbane, Australia

Ad hoc Reviewer, Austrian Science Fund (FWF) 2021-present

Full Professor Promotion Review 2020
Department of Biochemistry, Howard University

Chair, External Advisory Board 2020-present

Consortium on Disparities in Urologic Conditions (ConDUC)

Ad hoc Reviewer, Prostate Cancer Review Panel 2020-present
American Cancer Society

Member, Strategic Planning Group 2020-present
Nigeria-Diaspora Biomedical Research Program
National Universities Commission (NUC), Nigeria

Ad hoc Reviewer, Israel Science Foundation 2020-present

Ad hoc Member, ZCA1 SRB-2 (A1) S 2019-present
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)
Center for Scientific Review, National Institutes of Health

Ad hoc Member, ZCA1 SRB-E (M1) P 2019-present
Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)
Center for Scientific Review, National Institutes of Health

Member (Standing Membership for a 6-year term from 2019; Alternate Chair in 2020)
Cancer Cell Biology Study Section 2018-present
Center for Scientific Review, National Institutes of Health

Ad hoc Member, NCI Special Emphasis Panel NCORP Minority/Underse- 2018-present
rved Community Sites (ZCA1 SRB-H (M1) R)
Center for Scientific Review, National Institutes of Health

Organizer and Chairman, Annual TUFCCC/HC Regional 2016-2018
Comprehensive Cancer Health Disparity Partnership Research Symposium

Member, Curriculum Committee, PhD in Biochemistry Program 2017-present
The Graduate Center, City University of New York

Ad hoc Reviewer, Genesis Oncology Trust, New Zealand 2016

Member, Medicare Evidence Development & Coverage 2016-present
Advisory Committee (MEDCAC)
Centers for Medicare & Medicaid Services
US Department of Health and Human Services

Chair, 2016 Center for Translational and Basic Research 2015-2016
Annual International Symposium Planning Committee

Tenure Review 2015
Department of Biochemistry, Howard University

Member, The Graduate Center Dissertation Review Committee 2015
The Graduate Center, City University of New York

MA Advisor, and Member of Master's Advisory Committee (with 2014-2020
responsibility for admission to MA in Biology program)
Department of Biological Sciences
Hunter College of The City University of New York

Mentor, American Association for Cancer Research 2015
Special Program for High School Students
AACR Annual Meeting, Philadelphia, PA

Judge, American Association for Cancer Research 2014
Annual Undergraduate Student Caucus and Poster Competition
AACR Annual Meeting, San Diego, CA

Postdoctoral Peer Mentor 2012 - 2013
University of Florida, Gainesville, Florida.

Member, Experimental Pathology Innovative Grants Study Section, 2012 - 2013
University of Florida, Gainesville, Florida.

Judge, Graduate Students Research Day Poster Competition 2012
College of Medicine, University of Florida

Member, Seminar Panel for Interdisciplinary Program (IDP) for 2012
graduate students, College of Medicine, University of Florida.

Ad hoc Reviewer, Irish Health Research Board 2008

Chairman and coordinator, Postgraduate students seminar 2004 - 2006
series, School of Medicine, University of East Anglia, Norwich, UK.

Graduate Student Member, School-wide Research Committee 2004 – 2006
School of Medicine, University of East Anglia, Norwich, UK.

Captain, Medical Student Group, University of Ibadan 1996 - 2000
Ibadan, Nigeria.

Member, Editorial Board, Press Club, Alexander Brown Hall 1996 - 2000
University of Ibadan, Ibadan, Nigeria.

Member, Executive Board, Oyo State Medical Students Association 1996 - 2000
University of Ibadan, Ibadan, Nigeria.

## Journal Editorial Board Memberships

Associate Editor, Biomarker Insights
Associate Editor, Frontiers in Genetics
Associate Editor, Frontiers in Oncology
Academic Editor, PLoS ONE
Associate Editor, Frontiers in Immunology
World Journal of Clinical Oncology
PeerJ
Journal of Clinical and Translational Hepatology

## Ad hoc Journal Review

Nature Communications, Molecular Cancer Research, Oncotargets, Carcinogenesis, BMC Cancer, PLoS One, Cancer Causes & Control, The Prostate, Gut, American Journal of Gastroenterology, Alimentary Pharmacology and Therapeutics, Journal of Pharmacology and Experimental Therapeutics, Laboratory Investigation, British Journal of Nutrition, Expert Opinion on Therapeutic Targets, World Journal of Clinical Oncology, International Journal of Cancer, Genes, Frontiers in Genetics, Frontiers in Oncology, Aging, Molecular Therapy - Oncolytics

## Publications

*Peer-reviewed journal articles*

1. Johnson CK, Leung MM, Ma GX, **Ogunwobi OO**. Effective Recruitment Strategies Utilized to Examine Dietary Practices of Blacks in New York City in the Midst of the COVID-19 Pandemic. Journal of Racial and Ethnic Health Disparities. 2023, In Press.

2. Ma GX, Zhu L, Tan Y, Zhai S, Ma X, **Ogunwobi OO**, Yang WJ, Ting T, Kim S, Wang MQ. A Comparative Trial of Improving Care for Underserved Asian Americans Infected with Hepatitis B Virus. Digestive Diseases and Sciences. 2023, doi: 10.1007/s10620-023-07840-5.

3. Vickers A, Mahal B, **Ogunwobi OO**. Racism doesn't cause prostate cancer, it causes prostate cancer death. Journal of Clinical Oncology. 2023, DOI https://doi.org/10.1200/JCO.22.02203.

4. Zambrano CN, Lu W, Johnson C, Beeber M, Panitz A, Ibrahim S, Fraser M, Ma GX, Navder K, Yeh M, **Ogunwobi OO**. Dietary behavior and urinary gallic acid concentration differences among underserved elder racial and ethnic minorities in New York City. Cancer Causes & Control. 2022; 33(7):929-937. doi: 10.1007/s10552-022-01581-y.

5. Awah C, Winter J, **Ogunwobi OO**. Genome scale CRISPR Cas9a knockout screen reveals genes that control glioblastoma susceptibility to the alkylating agent temozolomide. All Life. 2022, 15 (1): 88–93, DOI: https://doi.org/10.1080/26895293.2021.2024895.

6. Akingboye A, Mahmood F, Amiruddin N, Reay M, Nightingale P, **Ogunwobi OO**. Increased risk of COVID-19 related admissions in active solid organ cancer patients in the West Midlands region of the United Kingdom: A Retrospective cohort study. BMJ Open. 2021;11: e053352. DOI: http://dx.doi.org/10.1136/bmjopen-2021-053352.

7. Awah C, Winter J, Mazdoom C, **Ogunwobi OO**. NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to Temozolomide (TMZ) via NELFB and RPS6KB2 interaction. Cancer Biology & Therapy. 2021, 27:1-11.

8. Naidoo M, Levine F, Gillot T, Orunmuyi AT, Olapade-Olaopa EO, Ali T, Krampis K, Pan C, Dorsaint P, Sboner A and **Ogunwobi OO**. MicroRNA-1205 regulation of FRYL in prostate cancer. Frontiers in Cell and Developmental Biology. 2021, 9:647485. DOI: 10.3389/fcell.2021.647485.

9. Asante-Asamani E, Pal G, Liu L, **Ogunwobi OO**. Prostac: a new composite score with potential predictive value in prostate cancer. Front. Oncol. 2021, 11:644665. DOI: 10.3389/fonc.2021.644665.

10. Levine F, **Ogunwobi OO**. Targeting PVT1 Exon 9 Re-Expresses Claudin 4 Protein and Inhibits Migration by Claudin—Low Triple Negative Breast Cancer Cells. Cancers 2021, 13 (5), 1046; https://doi.org/10.3390/cancers13051046.

11. Beales ILP, **Ogunwobi OO**. Leptin activates Akt in oesophageal cancer cells via multiple atorvastatin-sensitive small GTPases. Molecular and Cellular Biochemistry 2021; doi: 10.1007/s11010-021-04067-8.

12. **Ogunwobi OO**, Segura MF. Editorial: PVT1 in cancer. Front. Oncol. 2020, 10: 588786; doi: 10.3389/fonc.2020.588786.

13. **Ogunwobi OO**, Mahmood F, Akingboye A. Biomarkers in Colorectal Cancer: Current Research and Future Prospects. Int. J. Mol. Sci. 2020, 21(15), 5311; https://doi.org/10.3390/ijms21155311; selected as one of the Highly Cited Papers of International Journal of Molecular Sciences published in 2020.

14. Huaman J, **Ogunwobi OO.** Circulating Tumor Cell Migration Requires Fibronectin Acting through Integrin B1 or SLUG. *Cells* 2020, *9(7), 1594;* https://doi.org/10.3390/cells9071594.

15. Pal G, Di L, Orunmuyi A, Olapade-Olaopa EO, Qiu W, **Ogunwobi OO**. Population Differentiation at the PVT1 Gene Locus: Implications for Prostate Cancer. G3: Genes, Genomes, Genetics, 2020; 10 (7): 2257-2264.

16. Onagoruwa OT, Pal G, Ochu C, **Ogunwobi OO**. Oncogenic Role of PVT1 and Therapeutic Implications. Front. Oncol. 2020, 10:17, doi: 10.3389/fonc.2020.00017.

17. Alegbeleye BJ, **Ogunwobi OO**. Primary Diffuse Large B-Cell Lymphoma of the Breast: A Rare Case Report and Review of the Literature. International Journal of Scientific Advances. 2020, 1 (2): 79-86.

18. T.I. Shireman, A.C. Adia, Y. Tan, L. Zhu, J. Rhee, **O.O. Ogunwobi**, G.X. Ma, Online Versus In-Person Training of Community Health Workers to Enhance Hepatitis B Virus Screening Among Korean Americans: Evaluating Cost & Outcomes, Preventive Medicine Reports (2020), doi: https://doi.org/10.1016/j.pmedr.2020.101131.

19. Pal G, **Ogunwobi OO**. Copy number - based quantification assay for non - invasive detection of PVT1 - derived transcripts. PLoS ONE. 2019, 14(12): e0226620. https://doi.org/10.1371/journal.pone.0226620.

20. Pal G, Huaman J, Levine F, Orunmuyi AT, Olapade-Olaopa EO, Onagoruwa OT, **Ogunwobi OO**. Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells. Genes. 2019, 10(12), 964; https://doi.org/10.3390/genes10120964.

21. Harricharran T, **Ogunwobi OO**. Oxytocin and oxytocin receptor alterations decreased survival and increased chemoresistance in patients with pancreatic cancer. Hepatobiliary & Pancreatic Diseases International. 2020, DOI: 10.1016/j.hbpd.2019.12.002.

22. Anand P, Filipenko P, Huaman J, Lyudmer M, Hossain M, Santamaria C, Huang K, **Ogunwobi OO**, Holford M. Selective inhibition of liver cancer cells using venom peptide. Marine Drugs. 2019, 17(10), 587; https://doi.org/10.3390/md17100587. Featured in PBS/NOVA's "Beyond the Elements: Reactions": https://www.pbs.org/wgbh/nova/video/beyond-the-elements-reactions/

23. Zambrano C, Johnson C, Lu W, Beeber M, Panitz A, Wyka K, Ibrahim S, Fraser M, Bhimla A, Tan Y, Navder K, Yeh M, Ma GX, **Ogunwobi OO**. Dietary behavior

and urinary gallic acid concentrations in older minority residents of East Harlem, New York City. Journal of Racial and Ethnic Health Disparities. 2020, 7, 217–223; DOI: 10.1007/s40615-019-00649-x.

24. Agrawal R, Chen M, **Ogunwobi OO**, Bukhari Z, Haseeb MA, Martello LA. EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation In Vitro. Ann. Clin. Lab. Sci. 2020; 50(1):45–56.

25. Harricharran T, **Ogunwobi OO**. Emergence of neural regulatory mechanisms in carcinogenesis. World Journal of Clinical Oncology. 2019; 10 (8): 279-282.

26. **Ogunwobi OO**, Kumar A. Chemoresistance Mediated by ceRNA Networks Associated with the PVT1 Locus. Front Oncol 2019, 9: 834; doi: 10.3389/fonc.2019.00834.

27. Harricharran T, **Ogunwobi OO**. Oxytocin receptor genetic alterations in hepatocellular carcinoma. Springer Nature Comprehensive Clinical Medicine. 2019, 1(7), 523-526; doi: 10.1007/s42399-019-00085-2.

28. Huaman J, Naidoo M, Zang X, **Ogunwobi OO.** Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. *Cells* 2019, *8*, 618.

29. Derderian C, Orunmuyi AT, Olapade-Olaopa EO, **Ogunwobi OO**. PVT1 signaling is a mediator of cancer progression. Front. Oncol. 2019; 9: 502.

30. Halpern, M. T., Dodd, SJ, Fang, C. Y., Tan, Y., Zhu, L., **Ogunwobi, O. O**. & Ma, G. X. Evaluation of a transdisciplinary cancer research training program for under-represented minority students. Informing Science Institute. 2019: 99 -108; https://doi.org/10.28945/4343.

31. **Ogunwobi OO**, Ma GX. SPEECH: Synergistic Partnership for Enhancing Equity in Cancer Health. Cancer Health Disparities 2019; 4: e1.e5. doi:10.9777/chd.2019.1012.

32. **Ogunwobi OO**, Dibba O, Zhu L, Ilboudo A, Tan Y, Fraser MA, Ma GX. Hepatitis B Virus Screening and Vaccination in First-Generation African Immigrants: A Pilot Study. Journal of Community Health 2019; 44 (6) 1037–1043; https://doi.org/10.1007/s10900-019-00668-z.

33. **Ogunwobi OO**, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 2019; 25(19): 2279-2293.

34. Gao C, Xiao G, Piersigilli A, Gou J, **Ogunwobi O**, Bargonetti J. Context Dependent Roles of MDMX (MDM4) and MDM2 in Breast Cancer Proliferation and Circulating Tumor Cells. Breast Cancer Research 2019; 21 (1): 5.

35. Lerman B, Harricharran T, **Ogunwobi OO**. Oxytocin and cancer: An emerging link. World J Clin Oncol 2018; 9(5): 74-82.

36. Lee M, Zhu L, Wang MQ, Wei Z, Tan Y, Nguyen MT, **Ogunwobi OO**, Ma GX. Psychosocial Predictors of HBV Screening Behavior among Vietnamese Americans. Am J Health Behav. 2017 Sep 1;41(5):561-570. doi: 10.5993/AJHB.41.5.5.

37. Luu HN, Lin H, Sørensen K, **Ogunwobi OO**, Kumar N, Chornokur G, Phelan CM, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park J, Di Pietro G. miRNAs associated with Prostate Cancer risk and progression. BMC Urology 2017;17(1):18. doi: 10.1186/s12894-017-0206-6.

38. Das DK, **Ogunwobi OO**. A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer. RNA and Disease 2017; 4: e1503. doi: 10.14800/rd.1503.

39. Das DK, Ali T, Krampis K, **Ogunwobi OO**. Fibronectin and androgen receptor expression data in prostate cancer obtained from a RNA-sequencing bioinformatics analysis. Data in Brief, 2017, 11:131-135.

40. Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, Robinson BD, Osborne JR, **Ogunwobi OO**. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Experimental Cell Research. 2016; 348(2):190-200.

41. Spratt DE, Chan T, Waldron L, Speers C, Feng FY, **Ogunwobi OO**, Osborne JR. Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncol. 2016; 2(8):1070-4.

42. Das DK, Osborne JR, Park JY, **Ogunwobi OO**. miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer. Translational Oncology. 2016; 9(3): 236–241.

43. Ilboudo A, Chouhan J, McNeil BK, Osborne JR, **Ogunwobi OO**. PVT1 exon 9: a potential biomarker of aggressive prostate cancer? Int. J. Environ Res Public Health, 2016, *13*(1), 12; doi:10.3390/ijerph13010012.

44. Das DK, Durojaiye V, Ilboudo A, Naidoo MK, **Ogunwobi OO**. A "patient-like" orthotopic syngeneic mouse model of hepatocellular carcinoma metastasis. J Vis Exp, 2015; (104), e52858, doi:10.3791/52858.

45. Das DK, Naidoo MK, Ilboudo A, DuBois P, Durojaiye V, Liu C, **Ogunwobi OO**. Isolation and propagation of circulating tumor cells from a mouse cancer model. J Vis Exp, 2015; (104), e52861, doi: 10.3791/52861.

46. George TJ, **Ogunwobi OO**, Sheng W, Fan ZH, Liu C. “Tissue is the issue”: circulating tumor cells in pancreatic cancer. Journal of Gastrointestinal Cancer, 2014;45:222-225.

47. Sheng W, **Ogunwobi OO**, Chen T, Zhang J, George TJ, Liu C, Fan ZH. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip, 2014;14(1):89-98.

48. Beales IL, Garcia-Morales C, **Ogunwobi OO**, Mutungi G. Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B. Mol Cell Endocrinol, 2014, 382 (1): 150-158.

49. **Ogunwobi OO**, Puszyk W, Dong H, Liu C. Epigenetic upregulation of c-Met and HGF drives metastasis in hepatocellular carcinoma. PLoS One, 2013, 8(5): e63765.

50. Zhao X, Tian C, Puszyk W, **Ogunwobi OO**, Cao M, Wang T, Cabrera R, Nelson D, Liu C. OPA1 down-regulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Laboratory Investigation, 2013, 93(1):8-19.

51. **Ogunwobi OO**, Liu C. Therapeutic and prognostic importance of epithelial-mesenchymal transition in liver cancers: Insights from experimental models. Crit Rev Oncol Hematol, 2012, 83(3):319-28.

52. **Ogunwobi OO**, Wang T, Zhang L, Liu C. COX-2 and Akt mediate multiple growth factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol, 2012, 27 (3): 566-578 (**Editorial on pages 418-420**).

53. **Ogunwobi OO**, Liu C. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis, 2011, 28 (8): 721-31.

54. Zhao X, **Ogunwobi OO**, Liu C. Survivin inhibition is critical for bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. PLoS One, 2011, 6 (8): e21980.

55. Sirica AE, Dumur CI, Campbell DJ, Almenara JA, **Ogunwobi OO**, Dewitt JL. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol and Hepatol, 2009, 7 (11 Suppl): S68-78.

56. Beales ILP, **Ogunwobi OO**. Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in esophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int J Cancer, 2010, 126 (9) 2247-55.

57. Beales I, **Ogunwobi O**. Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation. J Mol Endocrinol, 2009, 42 (4): 305-18.

58. **Ogunwobi OO**, Beales ILP. Statins inhibit proliferation and induce apoptosis in Barrett's oesophageal adenocarcinoma cells. Am J Gastroenterol, 2008, 103 (4): 825-837 **(Editorial on pages 838-41).**

59. **Ogunwobi OO**, Beales ILP. Glycine-extended gastrin stimulates proliferation via JAK2- and Akt-dependent NF-KB activation in Barrett's oesophageal adenocarcinoma cells. Mol Cell Endocrinol, 2008, 296 (1-2): 94-102.

60. **Ogunwobi OO**, Beales ILP. Leptin stimulates proliferation of oesophageal adenocarcinoma cells via upregulation of epidermal growth factor receptor ligands. Br J Biomed Sci, 2008, 65 (3): 121-7.

61. **Ogunwobi OO**, Beales ILP. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol, 2008, 285 (1-2): 43-50.

62. **Ogunwobi O**, Mutungi G, Beales ILP. Leptin stimulates proliferation and inhibits apoptosis in Barrett's oesophageal adenocarcinoma cells by COX-2 dependent, PGE2 mediated transactivation of the EGF receptor and JNK activation. Endocrinology, 2006, 147(9): 4505-4516.

63. **Ogunwobi OO**, Beales ILP. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3-kinase/Akt. Int J Colorectal Dis, 2007, 22 (4): 401–409.

64. **Ogunwobi OO**, Beales ILP. Cyclo-oxygenase-independent inhibition of apoptosis and stimulation of proliferation by leptin in human colon cancer cells. Dig Dis Sci, 2007 52 (8): 1934-1945.

65. **Ogunwobi OO**, Beales ILP. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol, 2007, 274 (1-2): 60-68.

66. Beales ILP, **Ogunwobi OO**, Cameron E, El-Amin K, Mutungi G and Wilkinson M. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a functional and immunohistochemical study. BMC Cancer, 2007, 7: 97.

67. **Ogunwobi OO**, Beales ILP. The role of adiponectin in colitis. Gastroenterology, 2007, 132 (3): 1199-1200.

68. Beales ILP, **Ogunwobi O**. Glycine-extended gastrin inhibits apoptosis in colon cancer cells via separate activation of Akt and JNK pathways. Mol Cell Endocrinol, 2006, 247 (1-2): 140-149.

69. **Ogunwobi OO**, Beales ILP. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept 2006 134 (2-3): 105-113.

70. **Ogunwobi OO**, Beales ILP. Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase independent pathways. Regul Pept, 2006, 134 (1): 1-8.

71. Beales ILP, **Ogunwobi O**. Adipokines and gastrointestinal disease. Aliment Pharmacol Ther, 2006, 24: 1127.

*Peer-reviewed book chapters*

1. Huaman J, Bach C, Ilboudo A, **Ogunwobi OO**. Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma in Precision Molecular Pathology of Liver Cancer, Edited by Chen Liu, September 2017, Springer.

2. **Ogunwobi OO**. Leptin, Cell Cycle and Cancer in Leptin - Regulation and Clinical Applications, Edited by Sam Dagogo-Jack, December 2014, Springer.

*Articles undergoing peer-review*

Chidiebere U Awah, Yana Glemaud, Fayola Levine, Kiseok Yang, Afrin Ansary, Fu Dong, Leonard Ash, Junfei Zhang, Daniel Weiser, **Olorunseun O Ogunwobi**. Destabilized 3'UTR ARE therapeutically degrades ERBB2 in drug-resistant ERBB2+ cancer models. 2022;
bioRxiv 2022.08.14.503914; doi: https://doi.org/10.1101/2022.08.14.503914.

Priyanka Ghosh, **Olorunseun O Ogunwobi**. Intracellular interaction of FNDC1/FN1/AR/cMYC in prostate cancer cells. 2023;
https://www.biorxiv.org/content/10.1101/2023.02.23.529660v1; doi: https://doi.org/10.1101/2023.02.23.529660.

**Ogunwobi OO**, Boylu B, Ochu C. Stem Cell Therapy of Solid Organ Cancers in Comprehensive Hematology and Stem Cell Research, Edited by Nima Rezaei, Elsevier.

**Patents**

| | Title | Type | US/F | Status | Application serial # | Filed |
|---|---|---|---|---|---|---|
| **1** | METHODS FOR USING PVT1 EXON 9 TO DIAGNOSE AND TREAT PROSTATE CANCER | Utility | US | **Issued on December 19, 2017**; Patent number: US 9845472 | 15/345,463 | 11/7/2016 |
| **2** | miRNAs USEFUL FOR IDENTIFYING TARGETS ASSOCIATED WITH CANCER | Utility | US | **Issued on November 27, 2018**; Patent number: US 10,138,481 B2 | 15/338,704 | 10/31/2016 |

| | | | | | | |
|---|---|---|---|---|---|---|
| **3** | miRNAs USEFUL FOR IDENTIFYING TARGETS ASSOCIATED WITH CANCER | Utility | US | Non-provisional; published on March 21, 2019 | 16/199,326 | 11/26/2018 |
| **4** | METHODS FOR USING PVT1 EXON 9 TO DIAGNOSE AND TREAT PROSTATE CANCER | Utility | US | **Issued on July 9, 2019;** Patent number: US 10344283 | 15/829,263 | 12/1/2017 |
| **5** | PLASMID VECTOR FOR EXPRESSING A PVT1 EXON AND METHOD FOR CONSTRUCTING STANDARD CURVE THEREFOR | Utility | US | **Issued on January 18, 2022;** U.S. Patent number 11,225,666. | 16/356,635 | 3/18/2019 |
| **6** | METHODS OF USING PVT1 EXON 9 TO DIAGNOSE AND TREAT PROSTATE CANCER | Utility | US | **Issued on March 16, 2021;** Patent number: US 10,947,535 | 16/504,078 | 07/5/2019 |
| **7** | DESTABILIZED ARE 3'UTRs AS THERAPEUTICS FOR CANCER | Utility | US | Non-provisional patent application | 18/176,871 | 03/1/2023 |

**Notable media interactions**

https://twitter.com/seunogunwobi/status/1600187783435296768?s=20&t=AvHk_BrTr8n1HWlAaIkxBg

https://twitter.com/AfricaRch/status/1516196863044694016?s=20&t=AvHk_BrTr8n1HWlAaIkxBg

https://youtu.be/1s-Zx20o2zo

https://www.science.org/content/article/crispr-s-ancestry-problem-misses-cancer-targets-those-african-descent

**Invited Oral Presentations**

**Ogunwobi OO***. Invited presentation as guest lecturer to the 2023 Mass General Cancer Center Cancer Equity Colloquium, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Title: Inequities in cancer health outcomes: Can strategies leveraging noncoding RNA biology help? Saturday, April 22, 2023 in Boston, Massachusetts.

**Ogunwobi OO***. Invited presentation as guest lecturer to Queensborough Community College of The City University of New York. Title: Impacting prostate cancer disparity in Black men using RNA nanotherapeutics. Monday, March 20, 2023 in Queens, New York.

**Ogunwobi OO***. Invited presentation as guest lecturer to State University of New York Downstate Health Sciences University, Brooklyn, New York. Title: Leveraging noncoding RNA biology for clinical applications towards cancer health equity. Thursday November 10, 2022 in Brooklyn, New York.

**Ogunwobi OO***. Invited presentation to Coalition against Hepatitis in People of African Origin (CHIPO) – New York City. Title: Addressing Myths and Misconceptions about Hepatitis B among African Immigrant Communities around the United States. Webinar, Wednesday October 19, 2022.

**Ogunwobi OO***. Invited presentation as guest lecturer to the Winship Grand Rounds, Winship Cancer Institute, Emory University, Atlanta, Georgia. Title: Leveraging non-coding RNA biology for clinical applications in cancer. Wednesday October 5, 2022 in Atlanta, Georgia.

**Ogunwobi OO***. Invited presentation as guest lecturer to the Department of Pharmacology, University of Colorado, Anschutz Medical Campus, Colorado. Title: Leveraging non-coding RNA biology for clinical applications in cancer. Monday September 26, 2022 in Anschutz, Colorado.

**Ogunwobi OO***. Invited presentation as guest lecturer to the Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Georgia. Title: Leveraging non-coding RNA biology for clinical applications in cancer. Wednesday September 21, 2022.

**Ogunwobi OO***. Invited presentation to AcademyHealth Annual Research Meeting (ARM). Title: Prediction modeling in prostate cancer disparities in Panel: A Rubric for

Algorithmic Fairness for Predictive Analytics in Healthcare. Saturday June 4, 2022 in Washington, DC.

**Ogunwobi OO***. Invited presentation to Department of Biochemistry and Molecular Biology, Michigan State University. Title: Leveraging non-coding RNA biology for clinical applications in cancer. East Lansing, Michigan, Tuesday May 31, 2022.

**Ogunwobi OO***. Invited presentation to Coalition against Hepatitis in People of African Origin (CHIPO)'s national coalition. Title: Addressing Myths and Misconceptions about Hepatitis B among African Immigrant Communities around the United States. Webinar, Wednesday April 20, 2022.

**Ogunwobi OO***. Invited presentation to Partnerships to Advance Cancer Health Equity (PACHE) Program Meeting, Center to Reduce Cancer Health Disparities (CRCHD), National Cancer Institute (NCI). Title: Strengthening Institutional Commitment and Capacity. Online Conference, Monday, September 20, 2021.

**Ogunwobi OO***. Invited panel presentation to the City University of New York Scholarship and Innovation Celebration. Online seminar, May 17, 2021.

**Ogunwobi OO***. Invited presentation to the City University of New York Faculty Diversity and Inclusion Conference. Title: Training racial minority students at Hunter College for the cancer research workforce. Online seminar, April 15 - 16, 2021.

**Ogunwobi OO***. Invited presentation to the Department of Biological Sciences, City College of The City University of New York. Title: Mechanisms of PVT1 transcripts in prostate tumorigenesis. Online seminar, March 8, 2021.

**Ogunwobi OO***. Invited presentation to the Department of Structural and Cellular Biology, Tulane University School of Medicine. Title: Mechanisms of PVT1 transcripts in prostate tumorigenesis. Online seminar, February 24, 2021.

**Ogunwobi OO***. Invited presentation to Coalition against Hepatitis in People of African Origin (CHIPO) – National Call. Title: Biobehavioral factors related to hepatitis B virus infection and progression to liver cancer in African immigrants to the US. Online seminar, January 25, 2021.

**Ogunwobi OO***. Invited presentation to Nigeria-Diaspora Biomedical Research Summit – Online Seminar, Abuja, Nigeria. Title: Oncogenic PVT1 exon 9 induces aggressive prostate cancer, expression of KRT14, VIM, FN1, CAV1, and inhibits expression of CLDN4. Online Seminar, National Universities Commission, Abuja, Nigeria, July 1 - 3, 2020.

**Ogunwobi OO***. Invited presentation to Nigeria-Diaspora Biomedical Research Summit – Online Seminar, Abuja, Nigeria. Title: Grantwriting Session 2: Developing Specific

Aims Page. Online Seminar, National Universities Commission, Abuja, Nigeria, July 1 - 3, 2020.

**Ogunwobi OO***. Invited presentation to Coalition against Hepatitis in People of African Origin (CHIPO) – New York City. Title: Biobehavioral factors related to hepatitis B virus infection and progression to liver cancer in African immigrants to the US. New York, New York, January 29, 2020.

**Ogunwobi OO***. Invited presentation to the Inger Richter Seminar Series, Department of Biological Sciences, Hunter College of The City University of New York. Title: Functions and Mechanisms of PVT1-Derived Transcripts in Prostate Tumorigenesis. New York, New York, December 9, 2019.

**Ogunwobi OO***. Invited presentation to the Specialized Programs of Research Excellence (SPORE) Working Group Meeting, Weill Cornell Medicine. Title: Functions and Mechanisms of PVT1-Derived Transcripts in Prostate Tumorigenesis. New York, New York, November 20, 2019.

**Ogunwobi OO***. Invited presentation to the Asian American Studies Center, Hunter College of The City University of New York. Title: Cancer Health Disparities Research at Hunter College. New York, New York, November 18, 2019.

**Ogunwobi OO***. Invited presentation to the Institute for Translational Epidemiology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. Title: Functions and Mechanisms of PVT1-Derived Transcripts in Prostate Tumorigenesis. New York, New York, November 14, 2019.

**Ogunwobi OO***. Invited keynote presentation to the 5th International Conference on Human Genetics and Genetic Diseases and 11th International Conference on Genomics and Pharmacogenomics. Title: MicroRNA-1207-3p in metastatic castrate-resistant prostate cancer. Philadelphia, Pennsylvania, September 21, 2018.

**Ogunwobi OO***. Invited presentation to Human Genetics & Genetic Disorders 2018. Title: PVT1-encoded miR-1207-3p in aggressive prostate cancer. Webinar, April 16, 2018.

**Ogunwobi OO***. Invited presentation to the Clinical and Translational Science Center, Weill Cornell Medicine, Cornell University. Title: PVT1 Exon 9 And Aggressive Prostate Cancer in Black Men. New York, April 13, 2018.

**Ogunwobi OO***. Invited presentation to the 2nd Hunter College-CUNY/Weill Cornell Medicine Belfer Research Retreat. Title: Elucidating molecular mechanisms of aggressive prostate cancer in males of African ancestry. New York, March 16, 2018.

**Ogunwobi OO***. Invited presentation to Bard College. Title: MicroRNA-1207-3p in Prostate Cancer. Annandale, New York, March 1, 2018.

**Ogunwobi OO***. Invited presentation to the College of Medicine, University of Ibadan, Nigeria. Title: Molecular medicine: challenges and opportunities. Ibadan, Nigeria, August 30, 2017.

**Ogunwobi OO***. Invited presentation to the Department of Pathology, University of Ibadan, Nigeria. Title: Non-coding RNAs in solid organ cancers: prostate cancer as an example. Ibadan, Nigeria, August 23, 2017.

**Ogunwobi OO***. Invited presentation to the Dental School, University of Ibadan, Nigeria. Title: Non-coding RNAs in solid organ cancers: prostate cancer as an example. Ibadan, Nigeria, August 22, 2017.

**Ogunwobi OO***. Invited presentation to the Centre for Genomics and Precision Medicine, University of Ibadan, Nigeria. Title: Non-coding RNAs in solid organ cancers: prostate cancer as an example. Ibadan, Nigeria, August 17, 2017.

**Ogunwobi OO***. Invited presentation to Lagos State University Teaching Hospital, Lagos, Nigeria. Title: MicroRNA-1207-3p in Castration-Resistant Prostate Cancer. Ibadan, Nigeria, August 16, 2017.

**Ogunwobi OO***. Invited presentation to the Department of Medicine Grand Round, University of Ibadan, Nigeria. Title: Circulating tumor cell biology – a novel approach to elucidating the mechanisms of cancer metastasis. Ibadan, Nigeria, August 3, 2017.

**Ogunwobi OO***. Invited presentation to the Department of Obstetrics and Gynecology Grand Round, University of Ibadan, Nigeria. Title: Non-coding RNAs in solid organ cancers: prostate cancer as an example. Ibadan, Nigeria, August 2, 2017.

**Ogunwobi OO***. Invited presentation to the Department of Surgery Grand Round, University of Ibadan, Nigeria. Title: Non-coding RNAs in solid organ cancers: prostate cancer as an example. Ibadan, Nigeria, August 1, 2017.

**Ogunwobi OO***. Invited presentation to the Institute of Advanced Medical Research and Training, College of Medicine, University of Ibadan, Nigeria. Title: MicroRNA-1207-3p in Castration-Resistant Prostate Cancer. Ibadan, Nigeria, July 26, 2017.

**Ogunwobi OO***. Invited presentation to Bowen University Teaching Hospital, Ogbomoso, Nigeria. Title: MicroRNA-1207-3p in Castration-Resistant Prostate Cancer. Ibadan, Nigeria, July 25, 2017.

**Ogunwobi OO***. Invited presentation to the American Urological Association Annual Meeting 2017. Title: PVT1 Non-Coding RNAs in Aggressive Prostate Cancer in Men of African Descent. American Urological Association Annual Meeting, Boston, Massachusetts, May 15, 2017.

**Ogunwobi OO***. Invited presentation to the RCMI Translational Research Network (RTRN) Cancer Cluster Seminar. Title: PVT1 non-protein coding gene in aggressive prostate cancer in Black males. Webinar, February 2, 2017.

**Ogunwobi OO***. Invited presentation to the RCMI Translational Research Network (RTRN) Research Coordinating Center and Data Coordinating Center meeting. Title: Non-coding RNA-based biomarker discovery for clinical applications in prostate cancer in males of African ancestry. Webinar, February 1, 2017.

**Ogunwobi OO***. Invited presentation to the Inaugural Hunter College-CUNY/Weill Cornell Medicine Belfer Research Retreat. Title: PVT1 in prostate cancer in males of African ancestry & New initiative in cancer research and minority populations. New York, January 4, 2017.

**Ogunwobi OO***. Invited presentation to the Prostate Cancer Working Group, Weill Cornell Medicine, Cornell University. Title: PVT1 non-coding RNAs in Prostate Cancer. New York, December 7, 2016.

**Ogunwobi OO***. Invited presentation to the RCMI Translational Cancer Health Disparities seminar, City College of New York. Title: PVT1-derived non-coding transcripts in aggressive prostate cancer in males of African ancestry. New York, December 8, 2016.

**Ogunwobi OO***. Invited presentation to the 29th Annual International Symposium of the Center for Translational and Basic Research (CTBR), Hunter College. Title: PVT1 Non-Coding RNAs in Prostate Cancer. New York, May 5, 2016.

**Ogunwobi OO***. Invited presentation to the Research Centers in Minority Institutions (RCMI) Center for Environmental Health Distinguished Seminar Series, Jackson State University. Title: PVT1 non-coding RNAs in Prostate Cancer. Jackson, Mississippi, January 27, 2016.

Naidoo MK*, **Ogunwobi OO**. Invited presentation to the 2015 Annual Biomedical Research Conference for Minority Students (ABRCMS). Title: A Novel Polyisoprenylated Cysteinyl Amide Inhibitor, NSL-BA-055, Selectively Inhibits Proliferation of Hepatocellular Carcinoma Cells. Seattle, Washington, November 14, 2015.

Ilboudo A*, **Ogunwobi OO**. Invited presentation to the Science of Global Prostate Cancer Disparities Conference. Title: *PVT1* exon 9 in prostate cancer aggressiveness in Black men. Montego Bay, Jamaica, November 8, 2014.

**Ogunwobi OO*.** Invited presentation to the Department of Biology, Brooklyn College, City University of New York, New York. Title: Elucidating the mechanisms of cancer metastasis using circulating tumor cell biology. New York, September 18, 2014.

**Ogunwobi OO*.** Invited presentation to the Department of Medicine, Weill Cornell Medical College, New York. Title: Elucidating the mechanisms of cancer metastasis using circulating tumor cell biology. New York, April 23, 2014.

**Ogunwobi OO*.** Invited presentation to the School of Public Health, City University of New York, New York. Title: In search of a biomarker of aggressiveness and disparity in prostate cancer. New York, April 23, 2014.

**Ogunwobi OO*.** Invited presentation to the inaugural Experimental Pathology Postdoctoral Symposium of the Department of Pathology, Immunology and Laboratory Medicine of the University of Florida. Title: Circulating tumor cell biology: a novel approach for elucidating the mechanisms of cancer metastasis. Gainesville, Florida, October 24, 2013.

**Ogunwobi OO*.** Invited presentation to the College of Pharmacy and Pharmaceutical Sciences, Florida A & M University. Title: Progression and metastasis in solid cancers: role of epigenetics. Tallahassee, Florida, June 27, 2013.

**Ogunwobi OO*.** Invited presentation to the Center for Study of Gene Structure and Function at Hunter College, City University of New York. Title: Circulating tumor cell biology - a novel approach to elucidating the mechanisms of cancer metastasis. New York City, May 6, 2013.

**Ogunwobi OO*.** Invited presentation to the Division of Oncology, Cincinnati Children's Hospital Medical Center. Title: Circulating tumor cell biology - a novel approach to elucidating the mechanisms of cancer metastasis. Cincinnati, Ohio, February 26, 2013.

**Ogunwobi OO*.** Invited presentation to the Border Biomedical Research Center, Dept. of Biological Sciences, University of Texas at El Paso. Title: Circulating tumor cell biology - a novel approach to elucidating the mechanisms of cancer metastasis. El Paso, Texas, January 31, 2013.

**Ogunwobi OO***. Invited presentation for awardees of the Experimental Pathology Innovative Grant. Title: Mechanisms of metastasis in colon cancer. Gainesville, Florida, August 6, 2012.

**Ogunwobi OO***. Invited presentation in preparation for the T-32 Training Grant in Cancer Biology Annual Symposium. Title: Epithelial-mesenchymal transition and immunomodulation in hepatocellular carcinoma. Gainesville, Florida, January 18, 2012.

**Ogunwobi OO***. Invited presentation to the Department of Pathology, Immunology and Laboratory Medicine. Title: Epithelial-mesenchymal transition and immunomodulation in hepatocellular carcinoma. Gainesville, Florida, November 21, 2011.

**Ogunwobi OO***. Invited presentation to the Department of Surgery, University of Ibadan, Ibadan, Nigeria. Title: Molecular and cellular medicine: insights from esophageal adenocarcinoma and hepatocellular carcinoma. Ibadan, Nigeria, September 12, 2011.

**Ogunwobi OO***. Presentation to the University of Florida Liver Research Group. Title: Epithelial-mesenchymal transition in hepatocellular carcinoma. Gainesville, Florida, April 5, 2010.

**Ogunwobi OO***. Invited presentation to the Department of Pathology, Immunology and Laboratory Medicine. Title: Epithelial-mesenchymal transition in liver cancers. Gainesville, Florida, December 7, 2009.

**Ogunwobi OO***, Beales ILP. Oral presentation. Title: Globular adiponectin inhibits leptin-induced proliferation of oesophageal adenocarcinoma cells *in vitro*. United European Gastroenterology Week, Berlin, Germany, October 2006.

**Ogunwobi OO***, Beales ILP. Oral presentation. Title: Leptin stimulates proliferation of oesophageal adenocarcinoma cells via upregulation of epidermal growth factor receptor ligands. United European Gastroenterology Week, Berlin, Germany, October 2006.

**Ogunwobi OO***, Beales ILP. Oral presentation. Title: Leptin enhances the cell proliferative and antiapoptotic actions of acid in Barrett's adenocarcinoma. United European Gastroenterology Week, Copenhagen, Denmark, October 2005.

**Ogunwobi OO***, Beales ILP. Oral presentation. Title: Statins inhibit proliferation of oesophageal adenocarcinoma cells. United European Gastroenterology Week, Copenhagen, Denmark, October 2005.

* Presenter

## Poster presentations (selected)

Pal G, **Ogunwobi OO**. PVT1 exons 4A and 4B overexpressed in prostate cancer in black males regulate prostate epithelial cell proliferation and migration. 11th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, New Orleans, LA, November 2 – 5, 2018. (Pal G received a Scholar-in-Training Award supported by the National Cancer Institute's Center to Reduce Cancer Health Disparities in the amount of USD $1000)

Naidoo MK, Levine F, Gillot T, Ali T, Krampis K, Orunmuyi K, Olapade-Olaopa EO, **Ogunwobi OO**. MicroRNA-1205 regulation of FRYL and aggressive prostate cancer in men of African ancestry. 11th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, New Orleans, LA, November 2 – 5, 2018. (Naidoo MK received a Scholar-in-Training Award supported by

the National Cancer Institute's Center to Reduce Cancer Health Disparities in the amount of USD $1000)

Zambrano C, Beeber M, Panitz A, Tan Y, Ma G, Navder K, Yeh M, **Ogunwobi OO**. Diet and risk of cancer in minority populations in New York City. 11th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, New Orleans, LA, November 2 – 5, 2018.

Naidoo MK, Das DK, Ilboudo A, Orunmuyi A, Ogun GO, Adebayo S, Olapade-Olaopa EO, **Ogunwobi OO**. MicroRNA-1205 as a tumor suppressor in castration resistant prostate cancer. American Association for Cancer Research Annual meeting; Chicago, Illinois, USA, April 14-18 2018 (Naidoo MK received Scholar-in-Training Award supported by the Prostate Cancer Foundation in the amount of USD $1500).

**Ogunwobi OO**, Das DK, Orunmuyi A, Olapade-Olaopa EO. Two novel synthetic analogs of miR-1207-3p, NB5 and NB1207, target AR-V7 and c-MYC and demonstrate in vivo therapeutic efficacy in metastatic castrate-resistant prostate cancer (mCRPC). The 25$^{th}$ Biennial Congress of the European Association for Cancer Research (EACR25), 30 June to 3 July 2018, Amsterdam, Netherlands.

Das DK, Osborne JR, Park JY, **Ogunwobi OO**. miR-1207-3p, a novel biomarker of aggressive prostate cancer, displays differential expression in Caucasian men versus men of African ancestry. An AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines, December 4-7, 2015; Boston Renaissance Waterfront Hotel, Boston, MA

Das DK, Ilboudo A, **Ogunwobi OO**. miR-1207-3p as a potential prostate cancer biomarker in Black males. Eighth AACR Conference: The Science of Cancer Health Disparities in Ethnic Minorities and the Medically Underserved, Atlanta, GA, USA, November 13-16 2015 (Das DK received Scholar-in-Training Award supported by Center to Reduce Cancer Health Disparities (CRCHD) of the National Cancer Institute in the amount of USD $1850).

Ilboudo A, Das DK, **Ogunwobi OO**. PVT1 exon 9 is a potential non-invasive biomarker that regulates apoptosis and the cell cycle in aggressive prostate cancer in Black males. Eighth AACR Conference: The Science of Cancer Health Disparities in Ethnic Minorities and the Medically Underserved, Atlanta, GA, USA, November 13-16 2015.

Das DK, Ilboudo A, Osborne J, **Ogunwobi OO**. miR-1207-3p-induced downregulation of fibronectin is a novel regulatory pathway in prostate cancer. American Association for Cancer Research Annual meeting; Philadelphia, Pennsylvania, USA, April 18-22 2015.

Durojaiye V, Ilboudo A, Levine F, Osborne J, Park JY, **Ogunwobi OO**. miR-1205/FRYL as a novel regulatory mechanism in androgen-independent prostate cancer. American Association for Cancer Research Annual meeting; Philadelphia, Pennsylvania, USA, April 18-22 2015.

Ilboudo A, Ying C, **Ogunwobi OO**. *PVT1* exon 9 overexpression as a potential biomarker of prostate cancer in Black men. Seventh AACR Conference: The Science of Cancer Health Disparities in Ethnic Minorities and the Medically Underserved, San Antonio, TX, USA, November 9-12 2014.

**Ogunwobi OO**, Liu C. Circulating tumor cell miR-27a overexpression as a novel mechanism of hepatocellular carcinoma metastasis. American Association for Cancer Research Annual Meeting, San Diego, CA, USA, April 5-9 2014.

## Membership of professional bodies

Fellow, New York Academy of Medicine
Member, American Association for Cancer Research
Member, African-Caribbean Cancer Consortium
Member, American Heart Association

## Teaching Experience

Guest Instructor, PHA 6935: Current Topics on Health — 2020
College of Pharmacy
University of Florida

Instructor, BIOL 47117: Clinical Trials — 2020-present
Department of Biological Sciences
Hunter College, City University of New York

Instructor, BIOL 35000: Biology of Cancer — 2015-present
Department of Biological Sciences
Hunter College, City University of New York

Guest Instructor, BIOL 71400: Cell Biology — 2015
Department of Biological Sciences
Hunter College, City University of New York

Instructor, BIOL 47130: Biology of Cancer Progression — 2014-present
Department of Biological Sciences
Hunter College, City University of New York

Guest Instructor, BIOL 79302: Spring 2014 Seminar in — 2014-present
Molecular, Cell and Developmental Biology
PhD Biology Program
The Graduate Center, City University of New York

Co-Instructor, GMS 6903: Abstract and Manuscript Writing — 2013

for the Clinician/Scientist, University of Florida, Gainesville, Florida.

Problem based learning (PBL) tutor, School of Medicine, 2005 - 2008
University of East Anglia, Norwich, United Kingdom.

Communication skills tutor, School of Medicine, 2006 - 2008
University of East Anglia, Norwich, United Kingdom.

## Mentoring Experience

Previous mentees:

*Postdoctoral Fellow*
Gargi Pal (Hunter College, City University of New York, New York; progressed to Medical Writing Consultant at IQVIA)
Adeodat Ilboudo (Hunter College, City University of New York; joined Faculty at Bard Early College, New York)

*PhD Students*
Michelle Naidoo (City University of New York; progressed to NIH-funded postdoctoral fellow at Weill Cornell Medicine)
Dibash Das (City University of New York; progressed to Associate Director, Medical Communications at Haymarket Medical Network)
Jeanette Huaman (City University of New York, New York; progressed to Associate Medical Director at Imprint Science, VMLY&R)
Trisheena Harricharran (City University of New York, New York; progressed to Lecturer at Hunter College)

*Master's Students*
Bachelard Dieujeuste (Hunter College, City University of New York; now in the Genetics, Development and Stem Cells (GDSC) PhD program at University of Rochester School of Medicine and Dentistry)
Onayemi Onagoruwa (Hunter College, City University of New York, New York)
Fayola Levine (Hunter College, City University of New York, New York; accepted into the Biology PhD program at State University of New York Downstate Medical Center)
Sulaiman Abdelrahman (Hunter College, City University of New York; now a Pharmacist at Atlantic Health System, New Jersey)
Kiseok Yang (Hunter College, City University of New Yok)
Kamran Khan (Hunter College, City University of New York, New York)

*Postbaccalaureate Students*
Adithya Kumar (Hunter College, City University of New York, New York; transitioned into University of Cincinnati Medical School in summer 2020)
Pascal Dubois (Hunter College, City University of New York, New York)

Laura Figueroa (Hunter College, City University of New York; now a Clinical Research Coordinator at Memorial Sloan Kettering Cancer Center)

*Undergraduate Students*
Aneesa Razak (Hunter College, City University of New York, New York; now a Research Technician at Columbia University)
Mariya Kasiyanyk (Hunter College, City University of New York, New York)
Caprielle Peters (Hunter College, City University of New York, New York)
Andrew Fu (Hunter College, City University of New York, New York)
Anna O'Neil (Hunter College, City University of New York, New York; McNulty Scholar; accepted into Medical School)
Cristina Zambrano (Hunter College, City University of New York, New York; became a Research Education Coordinator; and now at Touro School of Osteopathic Medicine)
Cuong Bach (Hunter College, City University of New York, New York)
Helen Orins (Hunter College, City University of New York, New York)
Ubayed Muhith (Hunter College, City University of New York, New York; Undergraduate Research Fellow; now medical student at NYIT College of Osteopathic Medicine)
Michelle Naidoo (Hunter College, City University of New York; became a PhD student at City University of New York; now a Postdoc at Weill Cornell Medicine)
Ankita Dutta (Hunter College, City University of New York, New York; now a PhD student at City University of New York)
Ton Wang (University of Florida, Gainesville, FL; transitioned to Brown University Medical School)
Victoria Durojaiye (Hunter College, City University of New York, New York; now in Medical School)
Jazmine Joseph (Hunter College, City University of New York, New York, now a PhD student at Albert Einstein School of Medicine)
Michelle Koifman (Hunter College, City University of New York, New York; now in Internal Medicine Residency, Brooklyn, New York)
Tamara Gillot (Hunter College, City University of New York, Undergraduate Research Fellow)
Fayola Levine (Hunter College, City University of New York, New York; accepted into the Biology PhD program at State University of New York Downstate Medical Center)
Omar Dibba (Hunter College, City University of New York, New York; LSAMP Scholar)
Oreoluwa Alatishe (Hunter College, City University of New York, New York)
Akinbayo Caulcrick (Hunter College, City University of New York; now a Forensic Scientist)
Deepshikha Kewlani (Hunter College, City University of New York)
Camille Derderian (Hunter College, City University of New York)

*High School Students*
Omoyele Okunola (Howard Hughes Medical Institute, Hunter Science High School Summer Intern)
Jade Basem (New York University GSTEM program)

<u>Current mentees:</u>

*Faculty*
Timothy D. McClure, MD (Weill Cornell Medicine, New York)
Akinfemi Akingboye, MBBS, MD, FRCS (The Dudley Group Hospitals, United Kingdom)
Leng Chee Chang, PhD (University of Hawai'i at Hilo)
Akintunde Orunmuyi, MBBS, FCNP, MMed (University of Ibadan, Nigeria)
Amos Abolaji, PhD (University of Ibadan, Nigeria)
Akinyele Adisa, BDS, FMCDS (University of Ibadan, Nigeria)

*Postdoctoral Fellow*
Cicely Johnson (Hunter College Center for Cancer Health Disparities Research)
Chidiebere Awah (Hunter College Center for Cancer Health Disparities Research)
Fahad Mahmood, MBBS, PhD, MRCS (Department of General Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom)
Baris Boylu (Hunter College of The City University of New York)

*PhD Students*
Priyanka Ghosh (Hunter College, City University of New York)

*Master's Students*
Oluwatoyin Odumuwagun (Hunter College, City University of New York, New York)
Genevieve Fasano, MD (Weill Cornell Medicine, New York)
Solange Bayard, MD (Weill Cornell Medicine, New York)

*Postbaccalaureate Students*
Yana Glemaud (Hunter College, City University of New York, New York)
Hiram Caraballo (Hunter College, City University of New York, New York)

*Undergraduate Students*
Eric Song (Hunter College, City University of New York, New York)
Afrin Ansary (Hunter College, City University of New York, New York)
Nafeeza Ali (Hunter College, City University of New York, New York)
Fatima Galal El-Din (Hunter College, City University of New York, New York)

*High School Students*
Sam Donohoe (Packer Collegiate Institute, New York, New York)
Kayla (Packer Collegiate Institute, New York, New York)